NASDAQ : TPST
Tempest Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.4955 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.20M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.81M |
| Enterprise Value | 14.59M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 16.54M |
| Shares Outstanding | 16.54M |
| Shares Change (YoY) | +186.97% |
| Shares Change (QoQ) | +39.27% |
| Owned by Insiders (%) | 29.33% |
| Owned by Institutions (%) | 7.60% |
| Float | 11.46M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.38 |
| Quick Ratio | 0.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -931.14% |
| Return on Assets (ROA) | -79.37% |
| Return on Invested Capital (ROIC) | -108.68% |
| Return on Capital Employed (ROCE) | -417.94% |
| Weighted Average Cost of Capital (WACC) | -2.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$10.12M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -1.71 |
| 52-Week Price Change | -95.36% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 1.49 |
| Relative Strength Index (RSI) | 27.76 |
| Average Volume (20 Days) | 157,005 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 312,948 |
| Short Previous Month | 608,434 |
| Short % of Shares Out | 1.89% |
| Short % of Float | 2.73% |
| Short Ratio (days to cover) | 0.05 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.66M |
| Pretax Income | -40.47M |
| Net Income | -40.47M |
| EBITDA | -21.41M |
| EBIT | -21.66M |
| Earnings Per Share (EPS) | -$4.56 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 779,000 |
| Total Debt | 7.56M |
| Net Cash | -6.78M |
| Net Cash Per Share | -$0.41 |
| Equity (Book Value) | -1.09M |
| Book Value Per Share | -0.07 |
| Working Capital | -2.75M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -20.73M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 251,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -20.73M |
| FCF Per Share | -$1.25 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -186.97% |
| Shareholder Yield | -186.97% |
| Earnings Yield | -965.18% |
| FCF Yield | -252.95% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 9, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:13 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |